The company trades and distributes agricultural inputs like organic fertilizers and animal food supplements, while also holding licenses to trade in pharmaceutical ingredients and personal hygiene products.
The company lacks a durable competitive advantage, as evidenced by its razor-thin net margins of 0.4% and a business model primarily focused on trading commodities. The lack of proprietary technology or brand power is reflected in the high volatility of profits despite revenue growth.
Capital has been largely tied up in working capital and advances to related parties rather than productive assets. The company maintains a zero-debt balance sheet but fails to generate meaningful returns on its equity base, with EPS declining sharply over time.
The company collapsed after the massive related-party transaction authorizations proved to be a mechanism for siphoning capital rather than legitimate commerce. As revenue grew, the razor-thin 0.4% margins vanished entirely under the weight of uncollectible receivables and advances to entities controlled by the new management team. The total turnover of the board and promoters in 2024-2025 was the final warning sign before the business was hollowed out, leaving shareholders with a shell company whose assets consisted primarily of worthless IOUs from related parties.
RichFakir rates Scarnose International Ltd's business quality as poor — 28/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Scarnose International Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Scarnose International Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Scarnose International Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →